BMC Med:Stem cell therapy may reverse diabetes

Type I diabetes is caused by the body's own immune system attacking beta cells in the pancreas and requires daily injections of insulin to regulate the patient's blood sugar levels. A new approach, published in BMC Medicine, an open-access journal of the biomedical center, USES umbilical cord blood stem cells to reeducate diabetic patients' own T cells to activate pancreatic function and reduce the need for insulin.

Stem cell educators have slowly moved on to isolating lymphocytes from the blood of patients whose umbilical cord blood stem cells (CBSC) were immobilized from healthy donors. After two or three hours in the device, the lymphocytes are reeducated and returned to the patient. Monitor client progress at 4,12,24, and 40 weeks after treatment.

The C peptide is a protein fragment that ACTS as a by-product of insulin production and can be used to determine how well the cells are working. Until 12 weeks after treatment, all patients receiving treatment improved their c-peptide levels. The condition continued to improve for 24 weeks and remained so until the end of the study. This means that the daily dose of insulin needed to maintain blood sugar levels can be lowered. According to these results, glycosylated hemoglobin (HbA1C), an indicator of long-term glycemic control, also decreased with treatment in patients, but not in the control group.

Dr Yong Zhao, from the university of Illinois at Chicago, who led the multicentre study, explained: "we also see improved autoimmune control in these patients. Stem cell reeducation therapy increases the percentage of treated people with T lymphocytes in their blood that are regulated. Other markers of immune function, such as TGF-beta1, also improved. Our results suggest that this is an improvement in autoimmune control, mediated by the autoimmune regulator AIRE in umbilical cord blood stem cells, to allow the cells of the pancreas to recover.
Related News